Porton Biopharma says it is undergoing a manufacturing review to address US FDA concerns about the production of Jazz Pharmaceuticals’s orphan drug Erwinaze.
Servier has recruited CDMO MaSTherCell SA to manufacture its universal CAR-T candidate UCART19, licensed from the biotech Cellectis as an off-the-shelf cell therapy for leukemia.
The US FDA’s decision to let Juno Therapeutics restart its JCAR015 trial is positive, but the CAR-T sector must learn from safety and efficacy findings says French biotech TxCell.
Lundbeck has decided to stop making a cancer drug deeming the cost of securing API supplies too big and the likelihood to regulatory acceptance too small.
in-PharmaTechnologist presents its weekly round-up of the latest changes within the pharmaceutical job sector, including news from Takeda, Immune Design, and Pharmacyclics.
The possible sell-off of Enzon Pharmaceuticals’ biotechnology drugs business has come under fire by one of the firm’s shareholders, DellaCamera Capital Management, which says it is opposed to the move.
Researchers in the US have uncovered the mechanism underlying a
genetic tendency for some patients to be more susceptible to side
effects of drugs than others.
The first new leukaemia treatment approved specifically for
children in more than a decade was approved as Ash Stevens are to
manufacture Clofarabine, the active ingredient in Clolar, used to
treat acute lymphoblastic leukaemia (ALL).
Genes, which are linked to either resistance or sensitivity to four
major cancer drugs used to treat acute lymphoblastic leukaemia
(ALL) has led to the suggestion that these genes determine
treatment outcome and may represent future...